Open AccessJuxtaglomerular cell tumor: Clinical and immunohistochemical features
Author(s) -
Wang Fen,
Shi Chuan,
Cui Yunying,
Li Chunyan,
Tong Anli
Publication year - 2017
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12997
Subject(s) - immunohistochemistry , medicine , tfe3 , hypokalemia , cd34 , pathology , cyclin d1 , cancer , stem cell , gene expression , biology , biochemistry , genetics , promoter , cell cycle , gene
Juxtaglomerular cell tumor ( JGCT ) is a rare tumor, with approximately 100 cases reported in the literature. The authors respectively studied the clinical data of 11 patients diagnosed with JGCT in Peking Union Medical College Hospital from 2004 to 2014, and investigated the immunohistochemical profiles in 10 tumors. Nine of the 11 patients were diagnosed before the age of 40 years. Hypertension was present in all patients, while hypokalemia occurred in seven of 11 patients. Computed tomography detected JGCT s with a sensitivity of 100%. Immunoreactivities for CD 34 and vascular endothelial growth factor were observed in most tumor specimens, suggesting that JGCTs express a variety of vessel‐related immunohistochemical markers, although JGCT s are considered a tumor without abundant blood supply. Nuclear accumulation of cyclin D1 was common in JGCT s. Results from immunohistochemistry were negative for BRAF , HER 2, and TFE 3, suggesting that BRAF , HER 2, and TFE 3 genes might not play a part in tumorigenesis in JGCTs .